Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rituximab consolidation in high-risk CLL with suboptimal MRD response
2011-005174-27Phase 2Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Cliniques universitaires Saint-Luc. Started Feb 2012; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2011-005174-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005174-27.